A newly discovered mechanism governing the spread of toxic proteins in the brain offers a potential modern target for slowing the progression of Huntington’s disease, according to research published recently. The findings, stemming from work at Florida Atlantic University and collaborating institutions, pinpoint a cellular pathway that facilitates the transmission of harmful proteins between neurons, a key driver of this debilitating inherited disorder.
Huntington’s disease, affecting an estimated three to seven people per 100,000 worldwide, gradually erodes a person’s movement, memory and personality. Currently, there is no cure, and treatment focuses on managing symptoms. This research offers a glimmer of hope by identifying a specific process that could be interrupted to mitigate the disease’s devastating effects. The focus on interrupting the spread of the disease-causing protein represents a significant shift in therapeutic approaches to Huntington’s disease.
Scientists have long known that the toxic huntingtin protein spreads from cell to cell, but the precise method remained elusive. Now, researchers have identified “tunnelling nanotubes” – microscopic tube-like connections between neurons – as a key conduit for this transmission. These nanotubes aren’t solely detrimental; they can also facilitate communication between healthy cells. However, they can be exploited to spread harmful proteins, and the new study reveals how this hijacking occurs.
The research highlights the crucial role of two proteins: Rhes, and SLC4A7. Rhes, working in conjunction with SLC4A7 – a bicarbonate transporter typically involved in regulating cellular acidity – promotes the formation of these tunnelling nanotubes. This effectively creates pathways for the toxic huntingtin protein to move between neurons. Blocking this interaction significantly reduces the spread of the harmful protein, offering a potential therapeutic strategy.
Key Protein Partnership Identified
“This work fundamentally changes how we think about disease progression in Huntington’s,” said Dr. Srinivasa Subramaniam, Associate Professor in the Department of Chemistry and Biochemistry at Florida Atlantic University and a senior author of the study. “We’ve known that neurons somehow pass toxic proteins to one another but now we can see the machinery that makes that possible. By identifying SLC4A7 as a key partner of Rhes, we’ve uncovered a new and potentially druggable target to stop that spread at its source.”
The team utilized advanced protein-mapping techniques to demonstrate that Rhes directly binds to SLC4A7 at the cell membrane. This interaction triggers changes that encourage nanotube growth. Crucially, when SLC4A7 was blocked – either genetically or with drugs – nanotube formation was prevented, and the spread of the toxic protein was largely halted.
Promising Results in Animal Models
The findings extended beyond laboratory cell models. In mice engineered to develop Huntington’s disease, those lacking SLC4A7 exhibited a marked reduction in the transfer of toxic protein between neurons in the striatum, the brain region most affected by the condition. This suggests that targeting this newly identified pathway could slow disease progression by containing the damage before it spreads further.
Implications Beyond Huntington’s Disease
The implications of this discovery may extend beyond Huntington’s disease. Tunnelling nanotubes have also been implicated in other neurodegenerative conditions, including those involving tau protein, as well as cancer, where similar structures can help tumor cells share resources and resist treatment. “This research shines a spotlight on an entirely new way cells communicate in health and disease,” said Dr. Randy Blakely, Executive Director of the Florida Atlantic University Stiles-Nicholson Brain Institute. “By learning how harmful proteins physically move from cell to cell, we gain powerful new leverage points for therapy. The idea that we could slow or even halt disease progression by blocking these microscopic tunnels opens an exciting frontier for treating not only Huntington’s disease but a wide range of neurological disorders and cancers in the future.”
As scientists continue to unravel the complexities of cellular communication and the mechanisms underlying neurodegenerative diseases, this discovery provides a promising new avenue for therapeutic intervention. Further research will be critical to translate these findings into effective treatments for Huntington’s disease and potentially other related conditions.
Disclaimer: This article provides informational content and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your thoughts on this new research? Share your comments below, and please share this article with anyone who might find it helpful.
